How to access Gavreto from India, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian patient diagnosed with a RET-fusion-positive cancer, most commonly NSCLC or RET-altered thyroid cancer, may receive a prescription for Gavreto (pralsetinib) from their treating oncologist after molecular testing confirms the fusion. Gavreto is FDA-approved in the United States and is a selective RET inhibitor used in RET-fusion lung and thyroid cancers. In India, Gavreto may not be broadly stocked in hospital pharmacies due to the relatively low incidence of RET-altered disease, which is why your oncologist may be coordinating a personal-import pathway on your behalf.

This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Gavreto is a selective oral RET kinase inhibitor. Eligibility requires molecular confirmation of a RET fusion, typically by next-generation sequencing of tumour tissue or liquid biopsy. The manufacturer is Blueprint Medicines (with commercial arrangements involving Roche/Genentech historically; your oncologist will confirm the current US supply structure). Dosing is typically 400 mg orally once daily on an empty stomach, with monitoring for hypertension, pneumonitis, liver enzymes, haemorrhage, and cytopenias. Your oncologist will confirm the fusion and sequencing against your overall treatment plan.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Is Gavreto legally importable into India?

Yes, through the personal-import provision recognised under the Drugs and Cosmetics Act and the framework administered by the Central Drugs Standard Control Organization (CDSCO). The framework allows a patient, through their treating physician, to import a quantity of a medicine for personal use when the medicine has been approved by a recognised foreign regulator (FDA qualifies) and is prescribed for their named clinical need.

The named-patient mechanism rests on four anchors: (a) the medicine is approved by a recognised reference authority such as the FDA, (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the patient. Supporting documentation typically includes the physician's prescription, a clinical rationale letter, and customs declaration.

How the pathway works, step by step

1. Consultation with your treating oncologist. The decision to prescribe Gavreto is clinical, based on RET fusion status and treatment line. Your oncologist documents the rationale.
2. Prescription and clinical rationale letter. Your physician issues a prescription naming Gavreto and the planned duration.
3. Personal-import documentation. Reserve Meds prepares the personal-import package for customs clearance, including the physician letter, prescription, patient identifier, and product chain-of-custody.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
5. Temperature-controlled shipment. Gavreto is a stable oral capsule; shipments travel with tamper-evident packaging and customs documentation end to end.
6. Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming the RET fusion, tumour type, prior therapies, and Gavreto as the indicated treatment
• Verification of their Indian medical registration (state medical council)
• A current prescription naming the product, strength, and quantity
• Patient identifier (anonymised reference where possible)
• The planned treatment cadence (continuous daily therapy with monthly re-supply)

Reserve Meds provides a physician documentation kit bundling the templates Indian customs and CDSCO reviewers expect to see for personal-import of oncology oral therapies.

Costs and timing

Gavreto's US cash-pay drug-only reference price for a 30-day supply sits in an indicative 2026 drug-only range (delivered quote issued at intake) of roughly USD 22,000-25,000. Logistics, customs handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.

Indicative timing for first shipment arrival after cohort intake opens is 7-14 days from the moment a complete dossier is assembled. Subsequent re-supply cycles are generally faster once the pathway is established.

If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Gavreto specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Personal-import documentation package for your physician and for Indian customs handling.
• Logistics. Temperature-stable shipment coordination and customs clearance support.
• Concierge case lead. A named point of contact for your family and your physician throughout the process.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

Frequently asked

Is this legal in India? Yes, when executed through the personal-import provision under the Drugs and Cosmetics Act with appropriate physician documentation. See our trust and compliance page for our methodology.

Is Gavreto different from Retevmo? Both are selective RET inhibitors; your oncologist will choose based on clinical profile, tolerability considerations, and product availability. We do not advise on this choice.

Will private insurance cover this? Cash-pay is the default. Some Indian private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.

What happens if I miss a refill window? Our re-supply cadence is scheduled proactively at roughly Day 20 of each cycle so the next shipment arrives before current stock runs out.

Next step

For Gavreto coordination in India, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.

Or download the PDF guide ›

---

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Clinical & regulatory review: Reserve Meds AI Clinical and Regulatory Review (see /trust). Last medically reviewed: 2026-04-23.